Pheochromocytoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
*[[Refractory hypertension]] | *[[Refractory hypertension]] | ||
*[[Malignant hypertension]] | *[[Malignant hypertension]] | ||
==Prognosis== | ===Prognosis=== | ||
The 5-year survival in the setting of metastatic disease (whether identified at the time of initial diagnosis or identified postoperatively as recurrent disease) is 40% to 45% | The 5-year survival in the setting of metastatic disease (whether identified at the time of initial diagnosis or identified postoperatively as recurrent disease) is 40% to 45% | ||
==References== | ==References== | ||
Revision as of 20:50, 2 September 2015
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma natural history, complications and prognosis |
|
FDA on Pheochromocytoma natural history, complications and prognosis |
|
CDC on Pheochromocytoma natural history, complications and prognosis |
|
Pheochromocytoma natural history, complications and prognosis in the news |
|
Blogs on Pheochromocytoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Pheochromocytoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
Prognosis of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5 year survival rate of approximately 45%.[1] Massive release of catecholamines can causes damage to myocytes.
Natural History, Complication and Prognosis
Complication
The massive release of catecholamines in pheochromocytoma can cause damage to myocytes.[2] This damage may be due to either compromising the coronary microcirculation or by direct toxic effects on the myocytes.[2] Other complication may include:
Prognosis
The 5-year survival in the setting of metastatic disease (whether identified at the time of initial diagnosis or identified postoperatively as recurrent disease) is 40% to 45%
References
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc
- ↑ 2.0 2.1 Goldman 2011, pp. 327